26 June 2024 - Canada’s Drug Agency is launching a new one year learning period in our Scientific Advice program that will expand the type of guidance we offer to drug manufacturers to include those that are seeking advice after a “do not reimburse” recommendation is issued for their product.

During the learning period, we will provide advice on plans for new clinical evidence generation intended for drugs that were not recommended for reimbursement and that may be resubmitted to our Reimbursement Review program. To qualify, manufacturers must be planning to generate new clinical evidence that will address gaps identified in our final recommendation. New clinical evidence plans may include real-world evidence.

Read Canada's Drug Agency News